Starlight Cardiovascular, Inc.
Publicly observedSan Diego, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Diego | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Starlight Cardiovascular, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | W3TSK3T9QHJ7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant10 Aug 2026Publicly observed
NIH SBIR/STTR award: Commercialization Readiness of a Pulmonary Flow Restrictor for Hypoplastic Left Heart Syndrome
USD 499,952.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Feb 2022Publicly observed
NIH SBIR/STTR award: DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME
USD 1,166,665.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Feb 2022Publicly observed
NIH SBIR/STTR award: DEVELOPMENT OF A PULMONARY FLOW RESTRICTOR FOR HYPOPLASTIC LEFT HEART SYNDROME
USD 999,901.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant6 Aug 2021Publicly observed
NIH SBIR/STTR award: DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
USD 999,876.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant6 Aug 2021Publicly observed
NIH SBIR/STTR award: DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY
USD 999,918.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.